MSH|^~\&|LAB|ARH|||202002101444||ORU^R01|4165055|D|2.3|||AL|NE
PID|1||AB00006618|AB6617|LABTEST^CACTUS^||19621109|F||||||||||AB000407/18|9875909325
OBR|1|39170^LAB|00029538^1002:C00020R^LAB^100220:C20^39170|499.0048^QCOWCARM1^QC ONE WORLD CARDIAC MARKERS 1^^^||202002101425|202002101425|||||||202002101425||||||||||LAB|F||||
OBX|1|ST|500.5650^BNP R^B Type Natriuretic Peptide^^30934-4^30934-4|1|50^^Y|pg/mL|0-100|N||A^S|F|||202002101426
NTE|1||BNP Interpretive Guidelines:
NTE|2||< 100     pg/mL  Does not support CHF
NTE|3||100 - 250 pg/mL  Borderline zone CHF
NTE|4||250 - 400 pg/mL  Supports CHF
NTE|5||> 400     pg/mL  Strongly supports CHF
NTE|6||Contact designated speciality Pathologist if required.
OBX|2|ST|500.6900^CRPH^C-Reactive Protein High Sens^^30522-7^30522-7|1|5.0^^Y|mg/L|<7.5|N||A^S|F|||202002101426
NTE|1||This high sensitivity CRP method is sensitive to 0.3 mg/L
NTE|2||and is suitable for coronary artery risk assessment:
NTE|3||                         Less than 1.0 mg/L  low risk;
NTE|4||                         1.0 - 3.0 mg/L  intermediate risk;
NTE|5||                         Greater than 3.0 mg/L  high risk.
NTE|6||Values greater than 7.5 mg/L are significant for active
NTE|7||inflammation or infection and require follow up as
NTE|8||clinically needed. For consultation on specific patient
NTE|9||cases call your site Medical Biochemist. Interpretation
NTE|10||should be based on full history and other risk assessment
NTE|11||factors.